These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 21782422)

  • 1. Small-molecule androgen receptor downregulators as an approach to treatment of advanced prostate cancer.
    Bradbury RH; Hales NJ; Rabow AA; Walker GE; Acton DG; Andrews DM; Ballard P; Brooks NA; Colclough N; Girdwood A; Hancox UJ; Jones O; Jude D; Loddick SA; Mortlock AA
    Bioorg Med Chem Lett; 2011 Sep; 21(18):5442-5. PubMed ID: 21782422
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of AZD3514, a small-molecule androgen receptor downregulator for treatment of advanced prostate cancer.
    Bradbury RH; Acton DG; Broadbent NL; Brooks AN; Carr GR; Hatter G; Hayter BR; Hill KJ; Howe NJ; Jones RD; Jude D; Lamont SG; Loddick SA; McFarland HL; Parveen Z; Rabow AA; Sharma-Singh G; Stratton NC; Thomason AG; Trueman D; Walker GE; Wells SL; Wilson J; Wood JM
    Bioorg Med Chem Lett; 2013 Apr; 23(7):1945-8. PubMed ID: 23466225
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery of non-LBD inhibitor for androgen receptor by structure-guide design.
    Ryu BJ; Kim N; Kim JT; Koo TS; Yoo SE; Jeong SH; Kim SH; Kang NS
    Bioorg Med Chem Lett; 2013 Jul; 23(13):3887-90. PubMed ID: 23727044
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery of 3-aryloxy-lactam analogs as potent androgen receptor full antagonists for treating castration resistant prostate cancer.
    Guo C; Kephart S; Ornelas M; Gonzalez J; Linton A; Pairish M; Nagata A; Greasley S; Elleraas J; Hosea N; Engebretsen J; Fanjul AN
    Bioorg Med Chem Lett; 2012 Jan; 22(2):1230-6. PubMed ID: 22197140
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Androgen receptor down-regulation in prostate cancer with phosphorodiamidate morpholino antisense oligomers.
    Ko YJ; Devi GR; London CA; Kayas A; Reddy MT; Iversen PL; Bubley GJ; Balk SP
    J Urol; 2004 Sep; 172(3):1140-4. PubMed ID: 15311058
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Down-Regulation of prostate-specific antigen expression by ligands for peroxisome proliferator-activated receptor gamma in human prostate cancer.
    Hisatake JI; Ikezoe T; Carey M; Holden S; Tomoyasu S; Koeffler HP
    Cancer Res; 2000 Oct; 60(19):5494-8. PubMed ID: 11034093
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Steroid hormone receptors as targets for the therapy of breast and prostate cancer--recent advances, mechanisms of resistance, and new approaches.
    Hoffmann J; Sommer A
    J Steroid Biochem Mol Biol; 2005 Feb; 93(2-5):191-200. PubMed ID: 15860262
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Androgen receptor as a therapeutic target.
    Gao W
    Adv Drug Deliv Rev; 2010 Oct; 62(13):1277-84. PubMed ID: 20708648
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular modelling of the androgen receptor axis: rational basis for androgen receptor intervention in androgen-independent prostate cancer.
    Fletterick RJ
    BJU Int; 2005 Dec; 96 Suppl 2():2-9. PubMed ID: 16359432
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics, biodistribution and metabolism of a novel selective androgen receptor modulator designed for prostate cancer imaging.
    Yang J; Wu Z; Wu D; Darby MV; Hong SS; Miller DD; Dalton JT
    Int J Oncol; 2010 Jan; 36(1):213-22. PubMed ID: 19956850
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis and anticonvulsant activity of a new 6-alkoxy-[1,2,4]triazolo[4,3-b]pyridazine.
    Guan LP; Sui X; Deng XQ; Quan YC; Quan ZS
    Eur J Med Chem; 2010 May; 45(5):1746-52. PubMed ID: 20116141
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 1alpha,25-Dihydroxyvitamin D3 down-regulates expression of prostate specific membrane antigen in prostate cancer cells.
    Serda RE; Bisoffi M; Thompson TA; Ji M; Omdahl JL; Sillerud LO
    Prostate; 2008 May; 68(7):773-83. PubMed ID: 18247401
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel oligomeric proanthocyanidin derivatives interact with membrane androgen sites and induce regression of hormone-independent prostate cancer.
    Kampa M; Theodoropoulou K; Mavromati F; Pelekanou V; Notas G; Lagoudaki ED; Nifli AP; Morel-Salmi C; Stathopoulos EN; Vercauteren J; Castanas E
    J Pharmacol Exp Ther; 2011 Apr; 337(1):24-32. PubMed ID: 21205921
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HY251, a novel decahydrocyclopenta[a]indene analog, from Aralia continentalis induces apoptosis via down-regulation of AR expression in human prostate cancer LNCaP cells.
    Oh HL; Lee CH
    Bioorg Med Chem Lett; 2011 Mar; 21(5):1347-9. PubMed ID: 21315590
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Downregulation of androgen receptor expression by luteolin causes inhibition of cell proliferation and induction of apoptosis in human prostate cancer cells and xenografts.
    Chiu FL; Lin JK
    Prostate; 2008 Jan; 68(1):61-71. PubMed ID: 18008333
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evolution of the androgen receptor pathway during progression of prostate cancer.
    Hendriksen PJ; Dits NF; Kokame K; Veldhoven A; van Weerden WM; Bangma CH; Trapman J; Jenster G
    Cancer Res; 2006 May; 66(10):5012-20. PubMed ID: 16707422
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Androgen receptor protein is down-regulated by basic fibroblast growth factor in prostate cancer cells.
    Cronauer MV; Nessler-Menardi C; Klocker H; Maly K; Hobisch A; Bartsch G; Culig Z
    Br J Cancer; 2000 Jan; 82(1):39-45. PubMed ID: 10638964
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of androgen receptor in prostate cancer.
    Suzuki H; Ito H
    Asian J Androl; 1999 Sep; 1(3):81-5. PubMed ID: 11250774
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Androgen receptor-dependent and -independent mechanisms mediate Ganoderma lucidum activities in LNCaP prostate cancer cells.
    Zaidman BZ; Wasser SP; Nevo E; Mahajna J
    Int J Oncol; 2007 Oct; 31(4):959-67. PubMed ID: 17786330
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Selective role of an NH2-terminal WxxLF motif for aberrant androgen receptor activation in androgen depletion independent prostate cancer cells.
    Dehm SM; Regan KM; Schmidt LJ; Tindall DJ
    Cancer Res; 2007 Oct; 67(20):10067-77. PubMed ID: 17942941
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.